Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Chemist Warehouse is using MedAdvisor’s app in over 450 of its pharmacies under a new three-year deal
  • MedAdvisor’s app is designed to help users track and take medication and re-fill scripts
  • During the agreement, MedAdvisor is expected to earn $5 million in revenue
  • It will supply health programs to Chemist Warehouse customers, both online and instore
  • MedAdvisor’s share price is up nearly two per cent today, currently sitting at 5.4 cents per share

In its latest feat, MedAdvisor is teaming up with Chemist Warehouse and supplying its software to over 450 pharmacies.

MedAdvisor operates an app which assists users who are taking medication. It has reminders on when to take and information on how to take medications and has a re-fill script function.

The deal is locked in for a minimum of three years and is expected to generate more than $5 million in revenue for MedAdvisor. Payments will come from license fees and patient messaging fees.

MedAdvisor will provide health programs, which promote better understandings of health and medication, to Chemist Warehouse customers. The company advised this will significantly increase the audience for its health programs.

“Chemist Warehouse will drive improved health outcomes through the range of health programs available via MedAdvisor, which will be delivered both digitally and in-pharmacy,” CEO of MedAdvisor Robert Read said.

Health programs are predominately funded by the government or through pharmaceutical companies.

For eight years MedAdvisor has provided SMS services for Chemist Warehouse, who is ranked as one of Australia’s top 10 retailers.

“We have a long-standing relationship with MedAdvisor and have admired their cutting-edge technology and their ability to source valuable health programs for our patients,” Chemist Warehouse’s Co-founder and Director, Damien Gance, said.

Earlier this month, MedAdvisor raised $17 million to help fund its international expansion, which will target markets in the U.S., the U.K. and South East Asia. During the raise, it received an $11 million commitment from NASDAQ-listed HMS Holdings

MedAvisor’s share price is up slightly today by 1.89 per cent. Shares are currently trading for 5.4 cents each, as of 1:48 pm AEDT.

MDR by the numbers
More From The Market Herald
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).
Noxopharm (ASX:NOX) - CEO, Dr Graham Kelly

" Noxopharm (ASX:NOX) granted Australian and European patents

Noxopharm (NOX) has been granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy.

" ACCC granted injunction to block Virtus Health’s (ASX:VRT) purchase of IVF clinics

Australia’s Federal Court has granted the ACCC an interlocutory injunction to temporarily stop Virtus Health (VRT) from acquiring a string of fertility clinics.